News for Panbela Therapeutics Inc Stock (PBLA)

Panbela Provides Business Update and Reports Q4 and FY 2022 Financial Results

GlobeNewsWire • 03/16/23

Panbela to Host Fourth Quarter and Year End 2022 Earnings Conference Call on March 16, 2023

GlobeNewsWire • 03/08/23

Panbela Announces First Patient Enrolled in South Korea for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

GlobeNewsWire • 03/07/23

Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)

GlobeNewsWire • 03/01/23

Panbela Announces Closing of Approximately $15 Million Public Offering, and Regains Compliance with Nasdaq Listing Standards

GlobeNewsWire • 02/13/23

Panbela Announces Pricing of Approximately $15 Million Public Offering

GlobeNewsWire • 01/26/23

Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

GlobeNewsWire • 01/19/23

Panbela Announces 1-for-40 Reverse Stock Split effective January 13, 2023

GlobeNewsWire • 01/12/23

Panbela Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, in Collaboration with Indiana University School of Medicine and JDRF

GlobeNewsWire • 01/11/23

Panbela Receives Positive EMA Opinion on Orphan Designation for Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

GlobeNewsWire • 12/14/22

Panbela Announces First Patients Enrolled in Europe for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

GlobeNewsWire • 11/28/22

Panbela Therapeutics, Inc. (PBLA) Q3 2022 Earnings CallTranscripts

Seeking Alpha • 11/14/22

Panbela Provides Business Update and Reports Q3 2022 Financial Results

GlobeNewsWire • 11/10/22

Panbela Schedules Conference Call on, November 10, 2022, to Report 2022 Third Quarter Financial Results

GlobeNewsWire • 10/31/22

Panbela to Participate in the Roth Inaugural Healthcare Opportunities Conference

GlobeNewsWire • 10/06/22

Panbela Announces Pricing of Approximately $6 Million Public Offering

GlobeNewsWire • 09/30/22

Panbela Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

GlobeNewsWire • 09/29/22

Panbela Therapeutics, Inc.'s (PBLA) CEO Jennifer Simpson on Q2 2022 Results - Earnings Call Transcript

Seeking Alpha • 08/15/22

Panbela Provides Business Update and Reports Q2 2022 Financial Results

GlobeNewsWire • 08/15/22

Panbela Announces First Patient Enrolled in its Aspire Trial Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

GlobeNewsWire • 08/11/22

Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

GlobeNewsWire • 08/04/22

Panbela Schedules Conference Call on, August 15, 2022, to Report 2022 Second Quarter Financial Results

GlobeNewsWire • 08/01/22

Panbela Announces Publication of Preclinical Data Titled: Expanded Potential of the Polyamine Analogue SBP-101 (Diethyl Dihydroxyhomospermine) as a Modulator of Polyamine Metabolism and Cancer Therapeutic

GlobeNewsWire • 06/28/22

Panbela Therapeutics, Inc. Closes Acquisition of Cancer Prevention Pharmaceuticals, Inc.

GlobeNewsWire • 06/16/22

Panbela Therapeutics' (PBLA) CEO Jennifer Simpson on Q1 2022 Results - Earnings Call Transcript

Seeking Alpha • 05/14/22